Bourgeon Capital Management LLC Purchases 11,959 Shares of Eli Lilly and Company $LLY

Bourgeon Capital Management LLC boosted its position in Eli Lilly and Company (NYSE:LLY) by 1,311.3% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 12,871 shares of the company’s stock after purchasing an additional 11,959 shares during the period. Eli Lilly and Company comprises 2.0% of Bourgeon Capital Management LLC’s investment portfolio, making the stock its 24th biggest position. Bourgeon Capital Management LLC’s holdings in Eli Lilly and Company were worth $10,033,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Duquesne Family Office LLC grew its position in Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after purchasing an additional 32,640 shares in the last quarter. Corient IA LLC bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $570,000. LS Investment Advisors LLC grew its position in shares of Eli Lilly and Company by 1.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock valued at $1,933,000 after acquiring an additional 40 shares during the period. Cutter Capital Management LP bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $14,866,000. Finally, Prism Advisors Inc. bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $207,000. 82.53% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CEO David A. Ricks bought 1,632 shares of the stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 4,514 shares of company stock worth $2,894,841. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Trading Up 5.0%

Shares of LLY stock opened at $763.01 on Wednesday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock has a market capitalization of $722.16 billion, a price-to-earnings ratio of 49.87, a PEG ratio of 1.01 and a beta of 0.47. The company’s fifty day simple moving average is $733.15 and its two-hundred day simple moving average is $765.96.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the prior year, the company posted $3.92 EPS. The business’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on LLY. Guggenheim reduced their target price on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a research report on Wednesday, August 13th. Berenberg Bank reissued a “hold” rating and set a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Leerink Partners reissued a “market perform” rating and set a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Cantor Fitzgerald reduced their target price on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a research report on Wednesday, August 13th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $939.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.